China Should Focus On APIs And Pharmaceutical Preparations - CPEA Chairman
This article was originally published in PharmAsia News
Executive Summary
The China Pharmaceutical Enterprises Association's Chairman Yu Mingde remarked that China's pharmaceutical industry should focus on developing both APIs and pharmaceutical preparations
You may also be interested in...
China To Fund API Makers To Promote Exports
SHANGHAI - The Chinese government will spend RMB 5 billion ($760 million) to upgrade drug manufacturing quality assurance in an effort to help active pharmaceutical ingredient makers comply with global good manufacturing practices so they can export to the U.S. and Europe, an unnamed government official told the Shanghai Securities News
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.